Results 1 to 10 of about 29,580 (292)
IDCases, 2020 Ruxolitinib, a Janus kinase inhibitor, considerably improves symptoms of patients with polycythemia vera and primary or secondary myelofibrosis. However, its association with the development of infectious complications is a concern. Herein, we report the
Nobuyasu Hirai +11 more
doaj +2 more sources
Durable response to venetoclax, azacytidine, and ruxolitinib in chronic-phase myelofibrosis resistant to ruxolitinib: a case report and literature review [PDF]
Frontiers in OncologyMyelofibrosis (MF) is a philadelphia chromosome-negative chronic myeloprolifera- tive neoplasm.It has a worse prognosis than polycythemia vera and essential thrombocy- themia.At present,both Chinese and foreign guidelines recommend ruxolitinib as first ...
Xiaohong Liu, Xiujuan Zhang, Hongxia Shi
doaj +2 more sources
Impact of concomitant azoles on ruxolitinib treatment in patients with GVHD: post hoc analyses of REACH2 and REACH3 [PDF]
Blood Advances: Azole antifungal agents, commonly used for preventing invasive fungal infections in graft-versus-host disease (GVHD), are known to affect ruxolitinib metabolism.
Zahra Mahmoudjafari +6 more
doaj +2 more sources
Combinatorial BCL2/BCL2L1 expression predicts clinical response to ruxolitinib in myelofibrosis. [PDF]
Biomark ResColtro G +6 more
europepmc +3 more sources
c-Src binds to the cancer drug Ruxolitinib with an active conformation. [PDF]
PLoS ONE, 2014 The cancer drug Ruxolitinib is a potent janus kinase inhibitor approved for the treatment of the myeloproliferative neoplasms. In addition, Ruxolitinib has weak inhibitory activity against a panel of other kinases, including Src kinase.
Yankun Duan +3 more
doaj +1 more source
Blood Cancer Journal, 2023 The Janus kinase 2 (JAK2)-driven myeloproliferative neoplasms (MPNs) are chronic malignancies associated with high-risk complications and suboptimal responses to JAK inhibitors such as ruxolitinib.
Charly Courdy +18 more
doaj +1 more source
Frontiers in Pharmacology, 2021 Bronchiolitis obliterans syndrome (BOS) is a life-threatening pulmonary manifestation of chronic graft versus host disease (cGVHD) post-allogeneic hematopoietic stem cell transplantation (HSCT), without clear standard of care.
Yanmin Zhao +18 more
doaj +1 more source
Exploring redox vulnerabilities in JAK2V617F-positive cellular models
Hematology, Transfusion and Cell Therapy, 2021 Background: In Philadelphia chromosome-negative myeloproliferative neoplasm (MPN) models, reactive oxygen species (ROS) are elevated and have been implicated in genomic instability, JAK2/STAT signaling amplification, and disease progression. Although the
Keli Lima +2 more
doaj +1 more source
Enzalutamide and Ruxolitinib [PDF]
Hospital Pharmacy, 2013 The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Susan A, Hobson +2 more
openaire +2 more sources
Frontiers in Oncology, 2021 Myeloproliferative neoplasm (MPN) with PCM1-JAK2 rearrangement is a rare disease with poor prognosis and lacks uniform treatment guidelines. Several studies confirmed the efficacy of ruxolitinib in hematological malignancies with PCM1-JAK2 fusion, but ...
Yingxin Sun +16 more
doaj +1 more source